1
|
Selinger CP, Lenti MV, De Silvestri A. Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply. Aliment Pharmacol Ther 2022; 55:1070-1071. [PMID: 35362123 DOI: 10.1111/apt.16896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Affiliation(s)
| | - Marco Vincenzo Lenti
- Department of Gastroenterology, Leeds Teaching Hospitals, Leeds, UK.,Department of Internal Medicine, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
| | - Annalisa De Silvestri
- Biometry and Clinical Epidemiology, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy
| |
Collapse
|